News | July 07, 2022
Lonza to build large-scale fill & finish facility in Switzerland
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The introduction of Enverse is part of StimLabs' aim to simplify patient care for both physicians and the hospital systems
The AICVD tool can predict the risk of cardiovascular disease.
_256_384.jpg){kind=logo}
Meets the growing need for US-based API solubility and bioavailability enhancement services
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
Govt committed to supporting pharma companies with industry-friendly policies
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
Subscribe To Our Newsletter & Stay Updated
